Application of rutin-whey protein isolate particles in preparation of products for preventing, improving or treating skeletal muscle attenuation
By combining rutin with whey protein isolate, the rutin-whey protein isolate microparticles are prepared, which solves the problem of poor stability of the protein and rutin covalent complex, and achieves the prevention, improvement or treatment of skeletal muscles The significant effect of attenuation promotes bone health by scavenging free radicals and supplementing with high-quality proteins.
Patent Information
- Application Number
- CN202410995318.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
AI Technical Summary
The covalent complex formed by existing proteins and rutin limits the release of rutin and reduces protein solubility, resulting in poor effectiveness in preventing, improving or treating skeletal muscle attenuation.
By combining rutin with whey protein isolate, rutin-whey protein isolate is prepared, which improves the physical and chemical stability of rutin, and forms particulate dosage forms through ultrasound and other technical means, enhancing its packaging efficiency.
Effectively remove free radicals, supplement high-quality proteins, promote bone health, significantly improve the stability and packaging efficiency of rutin, and is used to prevent, improve or treat skeletal muscle attenuation.
Smart Images

Figure CN118902091A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of health food, and in particular to application of rutin-whey protein isolate particles in preparing products for preventing, improving or treating skeletal muscle attenuation. Background Art
[0002] Sarcopenia is an age-related geriatric syndrome characterized by decreased muscle mass, decreased muscle strength and / or decreased physical function. Although the onset of sarcopenia is insidious, it can cause serious body dysfunction, increase the risk of falls, disability and death in the elderly, and seriously damage the quality of life and health of the elderly. In addition to improving unhealthy lifestyles and increasing exercise, nutritional supplementation is also an effective way to prevent and treat sarcopenia in the elderly. Adequate protein intake is a necessary condition to ensure muscle mass and muscle quality. Studies have found that protein intake is positively correlated with the maintenance of muscle mass. Protein supplementation can effectively alleviate the aging-induced decrease in protein synthesis. Ensuring 25-30g of protein intake per meal can effectively stimulate the synthesis of myosin, and essential amino acids have an important influence on myosin synthesis. Among them, the three branched-chain amino acids leucine, isoleucine and valine are important components for maintaining the health of skeletal muscle in the elderly.
[0003] In addition, aging is accompanied by the accumulation of reactive oxygen species (ROS) in the body, which attacks normal cell structures and leads to irreversible cell function loss or apoptosis. Studies have shown that the higher the level of antioxidant components in the blood, the lower the risk of muscle strength loss. Some food-derived antioxidant components, such as resveratrol, salidroside, and calycosin, have been shown to have the effect of scavenging free radicals and improving the level of skeletal muscle oxidative stress.
[0004] Rutin is a flavonoid dietary polyphenol with multiple health effects such as antioxidant, anti-inflammatory, anti-cancer, anti-diabetic, and neuroprotective. When rutin was administered to mice fed a high-fat diet, mitochondrial biosynthesis and AMPK activity in skeletal muscle were significantly increased, showing a weight control effect. However, rutin has low water solubility, poor stability, and limited membrane permeability, and its physiological effects observed in in vitro studies are not always effectively converted into clinical effects. Whey protein isolate is an important protein ingredient and functional dietary nutrient preparation in the food industry, containing a variety of proteins such as α-lactalbumin, β-lactoglobulin, immunoglobulin, and lactoferrin. Studies have found that whey protein isolate is rich in essential amino acids, among which the content of three branched-chain amino acids, leucine, isoleucine, and valine, is as high as 20%, and plays an important role in protein metabolism, blood sugar stability, and lipid metabolism. The synergistic effect of rutin and whey protein isolate can effectively scavenge free radicals and supplement high-quality protein to promote bone health.
[0005] However, the covalent complex formed by protein and rutin not only limits the release of rutin, but also reduces the solubility of protein. Therefore, how to develop a safe, stable and efficient product for promoting bone health, preventing, improving or treating skeletal muscle attenuation has become an urgent problem to be solved. Summary of the invention
[0006] In view of the deficiencies of the prior art, the object of the present invention is to provide a use of rutin-whey protein isolate microparticles for promoting bone health in the preparation of products for preventing, improving or treating skeletal muscle attenuation.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] In a first aspect, the present invention provides a use of rutin-whey protein isolate microparticles in preparing a product for preventing, improving or treating skeletal muscle attenuation, wherein the rutin-whey protein isolate microparticles are prepared by a method comprising the following steps:
[0009] The rutin solution and the whey protein isolate solution are first mixed to obtain a mixed solution, and the mixed solution is added into an aqueous phase for second mixing to obtain the rutin-whey protein isolate microparticles.
[0010] In the present invention, by combining rutin and whey protein isolate, the physical and chemical stability of rutin is effectively improved and its encapsulation efficiency is improved. Among them, rutin, as a flavonoid dietary polyphenol, has multiple health effects such as anti-oxidation, anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotection. And whey protein isolate plays an important role in promoting protein metabolism, blood sugar stability and lipid metabolism. Rutin and whey protein isolate synergistically act in the preparation of products for preventing, improving or treating skeletal muscle attenuation, which can maintain and promote skeletal muscle health from the two aspects of scavenging free radicals and supplementing high-quality protein.
[0011] The product includes any one of food, medicine or health care product.
[0012] Preferably, the solvent of the rutin solution comprises anhydrous ethanol.
[0013] Preferably, the solvent of the whey protein isolate solution comprises water.
[0014] Preferably, the concentration of the rutin solution is 2-5 mg / mL, for example, it can be 2 mg / mL, 2.2 mg / mL, 2.5 mg / mL, 2.8 mg / mL, 3 mg / mL, 3.2 mg / mL, 3.5 mg / mL, 3.8 mg / mL, 4 mg / mL, 4.2 mg / mL, 4.5 mg / mL, 4.8 mg / mL, 5 mg / mL, etc. Other specific point values within this numerical range can be selected, which will not be described one by one here.
[0015] When the concentration of the rutin solution is within the above specific range, it has a more excellent effect on stabilizing the physical and chemical properties of rutin in the rutin-whey protein isolate particles and improving the encapsulation efficiency of rutin.
[0016] Preferably, the mass concentration of the whey protein isolate solution is 5-10wt%, for example, it can be 5wt%, 5.5wt%, 6wt%, 6.5wt%, 7wt%, 7.5wt%, 8wt%, 8.5wt%, 9wt%, 9.5wt%, 10wt% and the like, and other specific point values within this numerical range can be selected, which will not be described one by one here.
[0017] When the mass concentration of the whey protein isolate solution is within the above specific range, it has a more excellent effect on stabilizing the physical and chemical properties of rutin in the rutin-whey protein isolate microparticles and improving the encapsulation efficiency of rutin.
[0018] Preferably, the aqueous phase comprises 20%-45% ethanol solution, for example, it can be 20%, 22%, 25%, 28%, 30%, 32%, 35%, 38%, 40%, 42%, 45%, etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0019] Preferably, the first mixing is performed under ultrasonic conditions.
[0020] Preferably, the power of the ultrasound is 50-150W, for example, it can be 50W, 60W, 70W, 80W, 90W, 100W, 110W, 120W, 130W, 140W, 150W, etc. Other specific point values within this numerical range can be selected, which will not be described here one by one.
[0021] Preferably, the ultrasonic time is 8-15min, for example, it can be 8min, 8.5min, 9min, 9.5min, 10min, 10.5min, 11min, 11.5min, 12min, 12.5min, 13min, 13.5min, 14min, 14.5min, 15min, etc. Other specific point values within this numerical range can be selected, which will not be described here one by one.
[0022] Preferably, the adding of the aqueous phase is carried out dropwise.
[0023] Preferably, the second mixing method includes stirring.
[0024] Preferably, the stirring speed is 400-800rpm, for example, it can be 400rpm, 450rpm, 500rpm, 550rpm, 600rpm, 650rpm, 700rpm, 750rpm, 800rpm, etc. Other specific point values within this numerical range can be selected, which will not be described here one by one.
[0025] Preferably, the second mixing further includes drying and washing.
[0026] Preferably, the washing is performed under centrifugation conditions.
[0027] Preferably, the number of washing times is 2-5 times, for example, 2 times, 3 times, 4 times, 5 times, etc. Other specific point values within this numerical range can be selected and will not be described one by one here.
[0028] Preferably, the washing solvent comprises water.
[0029] Preferably, the centrifugal rotation speed is 3000-8000rpm, for example, it can be 3000rpm, 3500rpm, 4000rpm, 4500rpm, 5000rpm, 5500rpm, 6000rpm, 6500rpm, 7000rpm, 7500rpm, 8000rpm, etc. Other specific point values within this numerical range can be selected, which will not be described here one by one.
[0030] Preferably, the centrifugation time is 10-20 min, for example, it can be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 min, etc. Other specific point values within this numerical range can be selected, which will not be described here one by one.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] The present invention provides an application of rutin-whey protein isolate microparticles in the preparation of products for preventing, improving or treating skeletal muscle attenuation. Rutin and whey protein isolate act synergistically to effectively remove free radicals and supplement high-quality protein to promote bone health. At the same time, the microparticles are prepared in a microparticle dosage form, which effectively improves the physical and chemical stability of rutin and improves its encapsulation efficiency, maintains and promotes skeletal muscle health from the two aspects of removing free radicals and supplementing high-quality protein, and can be used to prepare products for preventing, improving or treating skeletal muscle attenuation. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1-1 is an analysis result diagram of the effect of rutin-whey protein isolate microparticles prepared in Example 1 on the ATP content in zebrafish skeletal muscle;
[0034] Figure 1-2This is a cross-sectional diagram showing the effect of the rutin-whey protein isolate microparticles prepared in Example 1 on the morphology and structure of zebrafish muscle cells;
[0035] Figure 2 This is a cross-sectional diagram showing the effect of the rutin-whey protein isolate microparticles prepared in Example 1 on the morphology and structure of mouse skeletal muscle cells. DETAILED DESCRIPTION
[0036] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0037] The rutin involved in the following examples is a product of model number Rutin (98%) purchased from Nanjing Jingzhu Biotechnology Co., Ltd.;
[0038] Whey protein isolate (98% by mass) was purchased from DAVISCO, USA;
[0039] The ATP content determination kit was purchased from Promega Corporation, USA, with batch number 451306.
[0040] In the result graphs of the following examples, lowercase letters indicate significant differences (p<0.05); uppercase letters indicate extremely significant differences (p<0.01); when the letters in each group are the same, the difference is not significant; when the letters are completely different, the difference is significant or extremely significant.
[0041] Example 1
[0042] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is as follows:
[0043] The rutin solution (solvent is anhydrous ethanol) that 2mL concentration is 4.0mg / mL is added to 2mL mass concentration and is mixed in the whey protein isolate solution (solvent is water) of 8wt%, and is ultrasonic 10min under the condition of 80W at power.The ultrasonic sample is added drop-wise to 30% ethanol solution of 20mL under the stirring speed of 550rpm, and after dropwising, continues to stir the 120min drying and solidifying microparticle.Use the ultrafiltration tube centrifugal washing 3 times (5000rpm, 15min, washing solvent is deionized water) of 100kD then, collect the concentrated microparticle suspension of upper strata subsequently, obtain described rutin-whey protein isolate microparticle.
[0044] Example 2
[0045] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is as follows:
[0046] The rutin solution (solvent is anhydrous ethanol) that 1.6mL concentration is 5.0mg / mL is added to 1.6mL mass concentration and is mixed in the whey protein isolate solution (solvent is water) of 5wt%, and is ultrasonic 8min under the condition of 100W at power.The ultrasonic sample is added drop-wise to 25% ethanol solution of 30mL under the stirring speed of 700rpm, and after dropwising, continues to stir the 120min drying and solidifying microparticle.Use the ultrafiltration tube centrifugal washing 3 times (6000rpm, 12min, washing solvent is deionized water) of 100kD then, collect the concentrated microparticle suspension of upper strata subsequently, obtain described rutin-whey protein isolate microparticle.
[0047] Example 3
[0048] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is as follows:
[0049] The rutin solution (solvent is anhydrous ethanol) that 3.2mL concentration is 2.5mg / mL is added to 3.2mL mass concentration and is mixed in the whey protein isolate solution (solvent is water) of 10wt%, and is ultrasonic 15min under the condition of 50W at power.The ultrasonic sample is added drop-wise to 40% ethanol solution of 30mL under the stirring speed of 450rpm, and after dropwising, continues to stir the 120min drying and solidifying microparticle.Use the ultrafiltration tube centrifugal washing 3 times (8000rpm, 18min, washing solvent is deionized water) of 100kD then, collect the concentrated microparticle suspension of upper strata subsequently, obtain described rutin-whey protein isolate microparticle.
[0050] Example 4
[0051] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is different from that of Example 1 only in that the concentration of the rutin solution is 0.5 mg / mL.
[0052] Example 5
[0053] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is different from that of Example 1 only in that the concentration of the rutin solution is 6.0 mg / mL.
[0054] Example 6
[0055] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is different from that of embodiment 1 only in that the mass concentration of the whey protein isolate solution is 3 wt %.
[0056] Example 7
[0057] This embodiment provides a rutin-whey protein isolate microparticle, and the preparation method thereof is different from that of embodiment 1 only in that the mass concentration of the whey protein isolate solution is 12 wt %.
[0058] Test Example 1
[0059] This test example tests the particle size and PDI of the rutin-whey protein isolate particles prepared in Examples 1-3. The particle samples are mixed with 30% ethanol solution to prepare 1 mg / mL solutions, and the pH value is adjusted to 7 for measurement. All measurements are performed at 25°C, and each value represents the average and standard deviation (SD) of three repeated tests. The particle size and PDI test results are shown in Table 1.
[0060] Table 1
[0061]
[0062]
[0063] As can be seen from the table, the particle size of the rutin-whey protein isolate microparticles prepared in Example 1 is about 170 nm, and the PDI is about 0.3, indicating that the particle size distribution of the rutin-whey protein isolate microparticles is relatively uniform. It shows that the rutin-whey protein isolate microparticle product prepared by the present invention has good stability and uniformity.
[0064] Test Example 2
[0065] This test example tests the drug loading and encapsulation efficiency of rutin in the rutin-whey protein isolate microparticles prepared in Examples 1-7.
[0066] Take 200 μL of the supernatant after the last centrifugation in the ultrafiltration centrifuge tube of Example 1-7 after resuspension, add it to the 96-well plate respectively, and add 200 μL of deionized water to the blank well as a blank control. Then measure the absorbance of each group of samples at 396 nm by a multifunctional microplate reader. Use the calibration curve established by the standard solution (the concentration of rutin in sodium hydroxide with a pH of 12 is 1-10 μg / mL) to determine the amount of rutin in the sample, and the standard curve equation is y=0.0206x-0.0012(R 2 =0.9992), where y is the absorbance value and x is the concentration of rutin (μg / mL).
[0067] The absorbance value of rutin in the sample was substituted into the rutin standard curve equation to calculate the corresponding content of rutin in the lower clearant. The drug loading capacity and encapsulation efficiency of the microparticle sample for rutin were calculated according to the following formulas: drug loading capacity (μg / mg) = (total rutin mass - lower clearant rutin mass) / total rutin - whey protein isolate microparticle mass; encapsulation efficiency (%) = (total rutin mass - lower clearant rutin mass) / total rutin mass × 100%. The results are shown in Table 2.
[0068] Table 2
[0069]
[0070]
[0071] From the data in Table 2, we can see that:
[0072] (1) It can be seen from Examples 1 to 3 that the rutin-whey protein isolate microparticles provided by the present invention can have a drug loading of up to 52 μg / mg for rutin, and an encapsulation rate of up to 70%. It can be seen that the present invention has prepared rutin-whey protein isolate microparticles with a high rutin encapsulation rate and drug loading.
[0073] (2) By comparing Example 1 with Examples 4-5, it can be seen that when the amount of rutin added is not within a specific range, the rutin encapsulation rate and drug loading of the prepared microparticle product are lower than those of Example 1. It can be seen that the microparticle product prepared by the present invention has higher stability and encapsulation effect by using a specific amount of rutin.
[0074] (3) By comparing Example 1 with Examples 6-7, it can be seen that the present invention further improves the stability and encapsulation effect of the prepared rutin-whey protein isolate microparticles by using a specific mass concentration of whey protein isolate.
[0075] Test Example 3
[0076] This test example tests the effect of the rutin-whey protein isolate microparticles prepared in Example 1 on preventing skeletal muscle attenuation.
[0077] Wild-type AB strain zebrafish 3 days after fertilization were randomly selected in a 6-well plate and divided into 6 groups, each with 30 tails, and the groups were: Example 1 group (intestinal injection, 1000 ng / tail rutin-whey protein isolate microparticles prepared in Example 1), rutin group (intestinal injection, 50 ng / tail), whey protein isolate group (intestinal injection, 950 ng / tail), positive control group (62.5 μg / mL water-soluble trimetazidine), model group and normal control group, 3 mL of water per well, except for the normal control group, the remaining groups were given water-soluble dexamethasone to establish a zebrafish sarcopenia model, and treated at 28°C for 96 h (48h liquid change), 10 zebrafish were randomly selected from each experimental group and placed in a 96-well plate, 1 tail / well, 200 μL / well, and tested using an ATP content determination kit, and data were collected by a multifunctional microplate reader software to analyze the ATP content in the zebrafish. The results are as follows Figure 1-1 The zebrafish in each group were fixed, dehydrated, embedded, sliced, and stained with H&E for histopathological examination to evaluate the improvement of the degree of muscle tissue lesions in the samples. The results are shown in Figure 1-2The statistical results were expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.
[0078] Depend on Figure 1-1 The statistical results show that the ATP content in the zebrafish skeletal muscle of the model group is significantly lower than that of the normal control group; while in the intervention groups of rutin and whey protein isolate, the ATP content in the zebrafish skeletal muscle is not significantly higher than that in the model group; and under the action of the rutin-whey protein isolate microparticle product prepared in Example 1, the ATP content in the zebrafish skeletal muscle of the group is significantly higher than that of the model group, and ATP is the energy source of the muscle during exercise. It can be seen that the rutin-whey protein isolate microparticle product provided by the present invention effectively increases the ATP content in skeletal muscle, which can effectively enhance skeletal motor ability, prevent skeletal muscle attenuation, and improve skeletal muscle function.
[0079] Depend on Figure 1-2 The cell morphology and structural analysis of the zebrafish skeletal muscle showed that the zebrafish muscle tissue in the normal control group had normal morphology, with thin and long muscle cells in a fibrous shape, closely arranged, and light and dark stripes arranged alternately; while the muscle tissue structure of the model group was loose and irregularly arranged, indicating that the model was successfully established; the looseness of the zebrafish muscle tissue in the positive control group was improved, and the arrangement was more regular than that in the model control group, indicating that trimetazidine has a therapeutic effect on sarcopenia; and the degree of zebrafish muscle tissue lesions in the rutin group, whey protein isolate group and Example 1 group were all improved to a certain extent compared with the model group, among which the muscle fiber structure of the zebrafish skeletal muscle in Example 1 group was closest to the normal control group, indicating that the rutin-whey protein isolate microparticle product provided by the present invention showed a significant effect in improving sarcopenia.
[0080] Test Example 4
[0081] This test example tests the effect of the rutin-whey protein isolate microparticles prepared in Example 1 on improving skeletal muscle function.
[0082] Select 8-week-old SPF male C57BL / 6J mice and randomly divide them into 5 groups, wherein the blank group is gavaged with sodium carboxymethylcellulose (CMC-Na) solution and injected with normal saline; the model group is gavaged with CMC-Na solution and injected with D-galactose to induce the generation of skeletal muscle attenuation symptoms; the rutin group is gavaged with rutin and CMC-Na solution and injected with D-galactose, the whey protein isolate group is gavaged with whey protein isolate solution and injected with D-galactose; the embodiment 1 group is gavaged with rutin-whey protein isolate solution and injected with D-galactose. The gavage volume and injection volume are 10mL / kg according to the weight of mice, the sample concentration of the rutin group is 10.3mg / mL, the sample concentration in the whey protein isolate group is 4.75mg / mL, and the sample solubility in the embodiment 1 group is 5mg / mL, and the dosage of rutin and whey protein isolate is consistent with the content of the two in the rutin-whey protein isolate solution of the embodiment 1 group. Gavage and injection were performed once a day for 11 weeks, and the mice were suspended by their tails from the 9th to 10th week to keep their hind limbs off the ground. After the 11th week, the gastrocnemius muscles of the mice were collected and observed by HE staining. Figure 2 shown.
[0083] Depend on Figure 2 The dyeing results show that:
[0084] (1) The muscle cross-section of mice in the blank group was intact, and the muscle cells were separated by white connective tissue with good morphology. The white connective tissue and muscle cells were arranged closely. The muscle fibers were basically the same size, the cell nuclei were clearly visible, and there was no fiber breakage or cell morphology change. No inflammatory cell infiltration was observed.
[0085] (2) The muscle cross-section of the mice in the model group was not complete, the white connective tissue and muscle cells were arranged loosely, the muscle fibers were inconsistent in size, the nuclei were blurred, the intermuscular spaces were widened, some muscle fibers were swollen, the interstitium was edematous, a large number of inflammatory cells were infiltrated between some muscle cells, some muscle fibers were broken and the cell morphology was changed, small pieces of red blood cells were seen between the muscle cells, and some fibrinoid and vacuolar changes were also seen.
[0086] (3) The muscle cross-section of mice in the rutin group was basically intact, and the white connective tissue and the space between the muscle cells were arranged loosely. The size of the muscle fibers was inconsistent, and the nuclei were blurred. The intermuscular spaces were widened, some muscle fibers were swollen, the interstitium was edematous, some inflammatory cells were infiltrated between some muscle cells, and some muscle fibers were broken and the cell morphology was changed. Compared with the mice in the model group, the degree of skeletal muscle structure lesions in the rutin group showed a certain degree of improvement.
[0087] (4) The muscle cross-section of mice in the whey protein isolate group was basically intact, the white connective tissue and the part between the muscle cells were arranged loosely, the size of the muscle fibers was inconsistent, the nucleus was blurred, the intermuscular space was widened, some muscle fibers were swollen, the interstitium was edematous, some inflammatory cells were infiltrated between some muscle cells, some muscle fibers were broken and the cell morphology was changed, small pieces of red blood cells were seen between the muscle cells, and some cellulose-like and vacuolar changes were also seen. Compared with the mice in the model group, the degree of skeletal muscle structure lesions in the whey protein isolate group showed a certain degree of improvement.
[0088] (5) The muscle cross-section of the mice in Example 1 group was basically intact, the white connective tissue and the space between the muscle cells were arranged loosely, the muscle fiber sizes were inconsistent, the cell nuclei were blurred, the intermuscular spaces were widened, some muscle fibers were swollen, the interstitium was edematous, some inflammatory cells were infiltrated between some muscle cells, and some inflammatory cells were absorbed, which was closest to the skeletal muscle structure morphology of normal mice in the blank group, indicating that the rutin-whey protein isolate microparticle product provided by the present invention has a certain protective and improvement effect on the skeletal muscle structure.
[0089] In summary, in the present invention, by combining rutin and whey protein isolate, the physical and chemical stability of rutin is effectively improved and its encapsulation efficiency is improved. Among them, rutin, as a flavonoid dietary polyphenol, has multiple health effects such as antioxidant, anti-inflammatory, anti-cancer, anti-diabetic, and neuroprotective. And whey protein isolate plays an important role in promoting protein metabolism, blood sugar stability and lipid metabolism. Rutin and whey protein isolate synergistically act and are used in the preparation of products for preventing, improving or treating skeletal muscle attenuation, which can maintain and promote skeletal muscle health from the two aspects of scavenging free radicals and supplementing high-quality protein.
[0090] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0091] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0092] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A use of rutin-whey protein isolate microparticles in the preparation of a product for preventing, improving or treating skeletal muscle attenuation, characterized in that: The rutin-whey protein isolate microparticles are prepared by a method comprising the following steps: The rutin solution and the whey protein isolate solution are first mixed to obtain a mixed solution, and the mixed solution is added into an aqueous phase for second mixing to obtain the rutin-whey protein isolate microparticles.
2. The use according to claim 1, characterized in that: The solvent of the rutin solution includes anhydrous ethanol.
3. The use according to claim 1, characterized in that: The solvent of the whey protein isolate solution includes water.
4. The use according to claim 1 or 2, characterized in that: The concentration of the rutin solution is 2-5 mg / mL.
5. The use according to claim 1 or 3, characterized in that: The mass concentration of the whey protein isolate solution is 5-10wt%.
6. The use according to claim 1, characterized in that: The aqueous phase includes 20%-45% ethanol solution.
7. The use according to claim 1, characterized in that: The first mixing is performed under ultrasonic conditions; Preferably, the power of the ultrasound is 50-150W; Preferably, the ultrasonication time is 8-15 min.
8. The use according to claim 1, characterized in that: The adding of the aqueous phase is carried out by dropwise addition; Preferably, the second mixing method includes stirring; Preferably, the stirring speed is 400-800 rpm.
9. The use according to claim 1, characterized in that: The second mixing further includes drying and washing; Preferably, the washing is performed under centrifugal conditions; Preferably, the number of washings is 2-5 times; Preferably, the washing solvent comprises water.
10. The use according to claim 9, characterized in that: The centrifugal speed is 3000-8000rpm; Preferably, the centrifugation time is 10-20 min.
